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Abstract
Background: DNA methylation patterns have been shown to significantly correlate with different
tissue types and disease states. High-throughput methylation arrays enable large-scale DNA
methylation analysis to identify informative DNA methylation biomarkers. The identification of
disease-specific methylation signatures is of fundamental and practical interest for risk assessment,
diagnosis, and prognosis of diseases.
Results: Using published high-throughput DNA methylation data, a two-stage feature selection
method was developed to select a small optimal subset of DNA methylation features to precisely
classify two sample groups. With this approach, a small number of CpG sites were highly sensitive
and specific in distinguishing lung cancer tissue samples from normal lung tissue samples.
Conclusion: This study shows that it is feasible to identify DNA methylation biomarkers from
high-throughput DNA methylation profiles and that a small number of signature CpG sites can
suffice to classify two groups of samples. The computational method we developed in the study is
efficient to identify signature CpG sites from disease samples with complex methylation patterns.
Background
DNA methylation, which occurs when a methyl (CH3)
group is added at the carbon 5 position of the cytosine
ring of a CpG dinucleotide, is one of the epigenetic events
that can affect gene expression without changing genomic
sequence [1]. For example, hypermethylation of CpG sites
in the promoter region was implicated as playing a role in
the inactivation of tumor suppressor genes [2,3]. DNA
methylation patterns have been shown to significantly
correlate with clinical phenotypes [4-6]. DNA methyla-
tion signatures are excellent biomarker candidates
because: 1) distinct DNA methylation profiles correspond
to different tissue types and disease states, and each type
or subtype of tumor has its own DNA methylation signa-
ture [5,7]; 2) DNA methylation patterns change at early
stages of disease progression, allowing earlier detection of
diseases [8]; 3) DNA methylation can be detected with
high sensitivity [9]; 4) DNA methylation biomarkers
could be detected from peripheral bio-fluid [10,11], such
as blood, when it is not possible to obtain disease-tissue
samples from patients. The identification of disease-spe-
cific methylation signatures is therefore of fundamental
and practical interest for risk assessment, diagnosis, and
prognosis of diseases.
High-throughput methylation arrays are now available to
determine DNA methylation levels of thousands of CpG
sites, simultaneously [4,5,12-14]. This technology enables
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large-scale DNA methylation analysis to identify informa-
tive DNA methylation biomarkers. For example, experi-
ments using high-throughput methylation arrays have
demonstrated that each of colon, breast, lung, and pros-
tate cancer cell lines has its own methylation signature [5].
It has also been shown that DNA methylation profiles
could clearly distinguish human embryonic stem cells
from cancer cells, adult stem cells, lymphoblastoid cells,
and normal cells [4]. Additionally, Bibikova et al. [5]
identified 55 CpG sites as the DNA methylation signature
to distinguish normal lung tissue samples from lung can-
cer tissue samples.
Although the profiles from high-throughput methylation
arrays contain a large number of CpG sites, many of them
are irrelevant or redundant and provide little discrimina-
tory information to classify samples. For clinical diagno-
sis, significant savings in cost can be achieved by
measuring and verifying methylation levels of only a
small number of CpG sites. Recent studies showed that a
small discriminative set of features was sufficient to better
classify samples in high-throughput gene expression anal-
ysis [15,16].
The Support Vector Machine (SVM) is a state-of-the-art
classification method (classifier or predictor) [17] that has
been widely used in microarray data analysis [18-21].
Although the SVM was designed to deal with datasets in
high-dimensional space [17], it has continued to suffer
from the "curse of dimensionality", that is, learning from
a small number of samples in a high-dimensional feature
space [21]. Including redundant and non-informative fea-
tures in the analysis may cause the influence of discrimi-
natory features to be lost in the noise, thus degrading the
accuracy of the classifier. A large feature set may achieve
low training error, but the ability to generalize the new
dataset will decrease, resulting in data overfitting [22].
Classification methods can be improved by feature selec-
tion, a process designed to select a small, optimal subset
of features from the original redundant feature set. In gen-
eral, feature selection methods fall into two categories: fil-
ter methods and wrapper methods [23]. Filter methods
select features independent of the classification method.
One typical filter method is individual feature ranking,
which is straightforward, computationally efficient, and
widely used for gene selection in gene expression data
analysis [24-26]. However, this method has several limita-
tions. First, feature redundancy is common in the selected
feature set and many features carry essentially the same
discriminatory information. In addition, this strategy
does not detect dependencies among features and lacks
the ability to determine which combination of features
achieves the best classification since individual feature
ranking evaluates each feature independently. In contrast
to filter methods, wrapper methods work with classifiers
to determine feature selection based on the predictive
accuracy of the classifiers [18,21]. Although wrapper
methods generally outperform filter methods, they are
typically computationally intensive [23] and may become
intractable in practice for large feature sets. SVM_RFE
(Recursive Feature Elimination) is a typical wrapper
method that has displayed excellent prediction ability in
microarray data analysis [18,21]. Genetic algorithms
(GAs) have been employed as feature selection methods
in high-throughput biological data analysis [27-29], but
are very time-consuming.
In this study, we investigated whether a small number of
signature CpG sites are sufficient to predict phenotypic
classes of two sample groups. A biomarker discovery algo-
rithm was developed. This algorithm, here referred to as
FW_SVM, uses a two-stage feature selection method by
combining a Filter method and a Wrapper method and
employs SVM as the classifier.
Methods
Datasets
We used three published datasets generated by the Illu-
mina GoldenGate® assay for DNA methylation (Illumina,
San Diego, CA), where the reported β value indicates the
methylation level of each CpG site [4,5]. The first dataset
included the DNA methylation profiles from 19 male and
25 female cell lines. The second dataset contained the
DNA methylation profiles of 37 human embryonic stem
cell (hES) and 24 cancer cell lines. The third dataset con-
tained 23 lung adenocarcinoma and 23 normal lung tis-
sue samples, 11 each from Philipps University of Marburg
(Germany) and 12 each from the Pennsylvania State Uni-
versity College of Medicine Tumor Bank.
The data in each dataset were split into training and test-
ing sets. The training set was used for feature selection and
classifier training, and the testing set was used to evaluate
algorithm performance.
Feature selection methods
FW_SVM
We developed a two-stage feature selection method (Fig-
ure 1) for FW_SVM, and it takes advantage of both filter
methods and wrapper methods. In the first stage of feature
selection, the filter method removes most of the statisti-
cally unimportant features and selects a list of the most
important CpG sites as signature candidates. In the sec-
ond stage, SVM_RFE (the algorithm of SVM_RFE is
described below) is used to remove redundant features
and select the smallest feature set achieving the best clas-
sification as signature CpG sites.
Two filter methods for stage 1, namely Principal Compo-
nent Analysis (PCA) and Wilcoxon rank sum test, were
tested separately in this study. PCA [30] is a multivariateBMC Bioinformatics 2008, 9:457 http://www.biomedcentral.com/1471-2105/9/457
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method that has been widely used for visualization of
high-dimensional data, including high-throughput bio-
logical data [31], in low-dimensional space. PCA is sel-
dom used for feature selection since each principal
component is a linear combination of all original features
and does not isolate or prioritize features. However, since
the first several principal components typically capture
most of the variability in the data, features that have big
projections on those principal components account for
the major source of data variance. Accordingly, those fea-
tures are likely good candidates as signature features for
classification purposes. In the first filter method, when
PCA was applied at the first feature selection stage, CpG
sites with an absolute loading value greater than 0.1 for
the first 10 principal components were selected as signa-
ture feature candidates taken by SVM_RFE at the second
stage. In the second filter method, we adopted the Wil-
coxon rank sum test. In comparison to the PCA approach
Two-stage feature selection method of FW_SVM Figure 1
Two-stage feature selection method of FW_SVM. In the first stage, Principal Component Analysis (PCA) and Wilcoxon 
rank sum test were tested separately as the feature filter. The RFE algorithm was used to select the signature feature set in the 
second stage.
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of selecting features with large variances across the entire
dataset, the individual feature ranking targeted directly
the classification goal and selected a list of the most differ-
entially methylated CpG sites as promising feature candi-
dates. The CpG sites from Wilcoxon rank sum test were
sorted by their p-values in ascending order. The top 50
most differentially methylated CpG sites were selected as
signature feature candidates with a restriction that the dif-
ferences of methylation level (β value) means between two
groups were greater than 0.15.
The feature selection method of FW_SVM was compared
with two popular feature selection methods: individual
feature ranking and SVM_RFE.
Individual feature ranking
Individual feature ranking selects features according to
their individual relevance. Its implementation is simple
and requires minimal run time. In this experiment, all
CpG sites were ranked in ascending order based on their
p-value from the Wilcoxon rank sum test. The Wilcoxon
rank sum test can be applied to data from any distribution
and is robust to outliers. An additional filter was applied
to remove CpG sites whose mean differences of methyla-
tion level (β value) between two groups were less than
0.15. The top-ranked 1, 2, 3, 5 or 10 of the most differen-
tially methylated CpG sites were selected as signature CpG
sites.
SVM_RFE
Recursive Feature Elimination (RFE) is a backward feature
selection method designed to find the best combination
of features for classification. Less important features, in
terms of the predictive accuracy of SVM, are successively
eliminated, allowing for the selection of only the best sub-
set of features. The RFE algorithm is outlined below:
Initialization
F = [1, 2, ..., n] is the subset of remaining features.
R = [] is the subset of ranked features.
Feature selection
1. For k = 1, 2, ..., n remove the kth feature and evaluate
the cross-validation error on the reduced feature set using
the training dataset.
2. Remove the feature with maximum cross-validation
error and include it to the top of R.
3. Repeat 1 and 2 for remaining features in F, until R con-
tains all ranked features.
SVM_RFE is an application of RFE using SVM as the clas-
sifier in the feature selection process [21]. In this study,
leave-one-out cross-validation was employed to evaluate
the classification performance of each feature set. Each
sample was excluded from the training set, one at a time,
and then classified based on the SVM trained from the
remaining samples. This procedure was repeated, in turn,
for all samples, and the cross-validation error was defined
as the sum of misclassifications. In the process, cross-vali-
dation error vs. the size of the feature set was recorded,
and the smallest subset of features with the least cross-val-
idation error was chosen as the final methylation signa-
ture.
Classification method
We selected SVM as the classification method to evaluate
signature features selected from different feature selection
approaches. Note that both SVM_RFE and FW_SVM also
took SVM as classifiers in their feature selection process.
SVM is a supervised machine learning technique to solve
classification problems [17]. It maps the data into a higher
dimensional space and constructs an optimal hyperplane
to maximize the separation margin between two classes.
In this study, we adopted Least Square SVM (LS-SVM), a
modified version of SVM that benefits from its computa-
tional simplicity and efficiency by solving a set of linear
equations instead of quadratic programming [32]. In a
training dataset of n samples, {xi, yi}, i = 1, 2, ..., n, where
xi ∈ Rd is a sample point with d features, and yi ∈ {-1, +1}
indicates the class of a sample. The class label of a new
sample is obtained by a decision function:
where parameters αi and b are optimized in the training
procedure such that the number of misclassifications on
the training set is minimized. K(xi, x) is a kernel function.
The LS_SVMlab toolbox http://www.esat.kuleuven.ac.be/
sista/lssvmlab/ was used in the implementation of
LS_SVM [33], and the RBF kernel function with default
parameters (γ = 10 and σ2 = 0.2) was adopted.
Performance testing and evaluation
Each of the three DNA methylation datasets generated by
Illumina high-throughput DNA methylation arrays [4,5]
was split into training and testing sets. The training set
contained approximately 2/3 of the samples and the test-
ing set included the remaining 1/3. The feature selection
methods were performed on training datasets. To validate
the features selected by each method, raw SVMs learned
from methylation profiles of the signature CpG sites in the
training set, and the trained SVMs were used to predict the
phenotypic classes of the samples in the testing set.
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In order to minimize bias introduced by data partitioning
and to accurately assess performance of the feature selec-
tion methods, each dataset was randomly partitioned into
training and testing sets multiple times. For individual
feature ranking and FW_SVM, the sensitivity, specificity,
accuracy, number of signature features, and running time
reported for each dataset represent the average across 100
independent runs. SVM_RFE was very time-consuming
with each run requiring several days to complete. There-
fore, its reported performance results are from only 5 ran-
dom partitions of training and testing datasets.
Sensitivity, specificity and accuracy were used to assess the
performance of classification:
where TP, FP, TN and FN represent true positives, false
positives, true negatives and false negatives, respectively.
Pathway analysis
Pathway Studio™ [34] with database Resnet 5.0 was used
to build gene interaction pathways from a list of genes
whose upstream CpG sites were differentially methylated.
All computational methods (except Pathway Studio) in
this study were implemented in MATLAB (The Math-
Works, Inc., Natick, MA) and run on a PC with a 3.8 GHz
CPU and 3.0 GB RAM.
Results and discussion
Comparison and discussion of feature selection methods
Figure 2 displays heat maps of the methylation status for
the 50 most differentially methylated CpG sites in the
three datasets, simply obtained from Wilcoxon rank sum
tests. Many CpG sites are methylated at different levels
among male and female cell lines (Figure 2a), reflecting
differential epigenetic regulation patterns by gender. Of
the top 25 most differentially methylated CpG sites, 21
are on the X-chromosome. Many genes display distinct
methylation profiles between cancer cell lines and hES
cell lines (Figure 2b), although it has been reported that
cancer cells share some characteristics with hES cells [35].
Considering only one feature is sufficient to obtain high
prediction accuracy for the cancer vs. hES cell line dataset
and for the male vs. female cell line dataset (Table 1). The
individual feature ranking method works well for the
datasets with distinct methylation patterns.
In contrast, the lung cancer and normal tissue data (Figure
2c) show different results. Perhaps due to the intrinsic
complexity of disease mechanisms, the lung cancer tissue
samples exhibited highly variable methylation patterns.
In the present case, the methylation profile of a single
CpG site is not sufficient to achieve accurate separation
between normal and lung cancer samples (Table 1). An
ideal DNA methylation signature, therefore, would con-
sist of a small subset of CpG sites to provide non-redun-
dant and complementary discriminative information.
SVM_RFE is a backward feature selection method and was
designed to find an optimal combination of features by
eliminating less-important features successively. How-
ever, due to its lengthy run times (Table 2), the computa-
tional cost of SVM_RFE likely limits its practical use in
high-throughput data analysis.
In FW_SVM, a two-stage feature selection method was
developed. The irrelevant and noisy information was
eliminated by a filter at the first stage, and then SVM_RFE
was used to detect the final optimal feature subset from
the remaining informative features at the second stage.
The first applied filter is PCA. Analysis of the normal and
lung cancer tissue dataset using PCA (Figure 3) found that
the loadings of most features fell near the origin, suggest-
ing that these features are likely not important nor
informative for classification, while features that have big
projections on those principal components account for
the major source of data variance and are likely good can-
didates as signature features for classification purposes.
We also tested individual feature ranking (Wilcoxon rank
sum test in the study) as the first-stage feature selection
method in the implementation of FW_SVM, in which we
selected the 50 most differentially methylated CpG sites as
feature candidates based on an estimated balance between
feature coverage and computational cost. FW_SVM pro-
vides the flexibility to select either a smaller or a larger
candidate feature set for distinguishing two sample
groups according to specific datasets or a user's prefer-
ences. In comparison with individual feature ranking and
SVM_RFE, as shown in Table 2, both versions of FW_SVM
achieved similar or better performance with more com-
pact feature size and a 2000-fold shorter run time than
SVM_RFE. By identifying and utilizing the complemen-
tary discriminative information in the signature feature
set, FW_SVM obtained similar or better predictive accu-
racy with only approximately two non-redundant CpG
sites as did individual feature ranking with 10 CpG sites.
Without other available DNA methylation datasets,
FW_SVM was tested on a benchmark microarray gene
Sensitivity
TP
TP FN
=
+
(2)
Specificity
TN
TN FP
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Heat maps of the 50 most differentially methylated CpG sites in three datasets Figure 2
Heat maps of the 50 most differentially methylated CpG sites in three datasets. The green color indicates low 
methylation level and red indicates high methylation level as shown in the colormap on the right side. (a) Male and female cell 
line samples. (b) hES and cancer cell line samples. (c) Normal and lung cancer tissue samples.BMC Bioinformatics 2008, 9:457 http://www.biomedcentral.com/1471-2105/9/457
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expression dataset [25]. The profiles of two genes identi-
fied by FW_SVM can classify Acute Myeloid Leukemia
(AML) and Acute Lymphoblastic Leukemia (ALL) sample
groups with the average accuracy of 98.8% (data not
shown).
An application of FW_SVM: signature CpG sites 
identification to classify lung cancer and normal tissue 
samples
The DNA methylation profiles in this study displayed
excellent biomarker characteristics. Accurate discrimina-
tion between two sample groups was achieved on the
basis of only a few CpG sites. In order to compare our
results with signature CpG sites obtained by Bibikova et
al. [5], we applied FW_SVM (the individual feature rank-
ing version in this experiment) to identify signature CpG
sites for normal and lung cancer tissue samples. We used
11 normal samples and 11 adenocarcinoma samples from
the Philipps University of Marburg (Germany) as our
training set and 12 normal samples and 12 adenocarci-
noma samples from the Pennsylvania State University
College of Medicine Tumor Bank as the testing set. From
the training set, FW_SVM selected two CpG sites, TNF-
1371 and TWIST1-524, as signature features. Based on
those two signature CpG sites, the predictor correctly clas-
sified all of the normal and lung cancer tissue samples in
the testing set and achieved better sensitivity and specifi-
city than the 55 CpG site markers identified by Bibikova
et al. [5].
To further verify the reliability of these two signature CpG
sites, we mixed the samples from these two datasets
together and randomly split them 100 times into a train-
ing set (containing 2/3 of the samples) and a testing set
(containing 1/3 of the samples). Raw SVMs were trained
on the profiles of these two CpG sites in the training sets,
and trained SVMs were used to predict the phenotype of
samples in the testing sets. The average sensitivity
achieved was 96%, and the average specificity was 100%.
We also investigated the biological pathway in which the
genes containing those two signature CpG sites are
involved. Given that many factors influence gene expres-
sion, DNA methylation changes do not necessarily trans-
late to changes of gene expression [36,37]. However, it
remains very likely that genes with differentially methyl-
ated CpG sites are involved in the development of lung
cancer. Pathway Studio™ software was used to analyze the
genes with the 100 most differentially methylated CpG
sites between normal and lung cancer tissue samples (p-
value < 0.005 and mean difference > 0.15). This analysis
detected direct expression interactions among many of
Table 1: Performance results of individual feature ranking
Dataset N* Sensitivity (%) Specificity (%) Accuracy (%) Run Time (seconds)
Male and female cell lines 1 99.4 100 99.7 0.18
2 99.8 100 99.9 0.18
3 100 100 100 0.18
5 100 100 100 0.18
10 100 100 100 0.18
Cancer and hES cell lines 1 95.0 99.9 98.0 0.34
2 96.1 99.9 98.5 0.35
3 96.6 100 98.7 0.35
5 99.6 99.8 99.8 0.35
10 100 99.5 99.7 0.35
Lung cancer and normal tissues 1 73.0 91.9 82.4 0.19
2 81.1 91.1 86.1 0.20
3 84.1 90.0 87.1 0.20
5 88.8 91.6 90.2 0.20
10 92.1 89.6 90.9 0.20
*N: The average number of selected signature CpG sites.
Table 2: Performance results of SVM_RFE and FW_SVM for lung cancer and normal tissue dataset
Method N* Sensitivity (%) Specificity (%) Accuracy (%) Run Time
SVM_RFE 3.6 95.0 85.0 89.9 5.1 days
FW_SVM with PCA 2.6 89.1 94.3 91.7 8.7 minutes
FW_SVM with individual feature ranking 2.2 87.4 94.1 90.8 8.4 minutes
*N: The average number of selected signature CpG sites.BMC Bioinformatics 2008, 9:457 http://www.biomedcentral.com/1471-2105/9/457
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those genes. As shown in Figure 4, TNF, a multifunctional
proinflammatory cytokine that belongs to the tumor
necrosis factor super family [38], is one of the hub genes
in this network. Its expression level, controlled by methyl-
ation regulation, may have a critical influence on other
genes. This may explain why the methylation status of a
CpG site in the promoter region of TNF is critical for clas-
sifying normal and lung cancer samples. TWIST, a basic
helix-loop-helix transcription factor implicated in cell lin-
eage determination and differentiation [39], is found
upstream of TNF in this network and its role in cancer has
been studied broadly [39-42].
In this study, we identified the smallest subset of CpG
sites required for precise classification of lung cancer and
normal tissue samples, with every signature CpG site con-
taining necessary, non-redundant and mutual informa-
tion in the context of others. All the signature CpG sites
identified are important biologically, but it is not neces-
sary to include all important CpG sites for classification
purposes.
While these two signature CpG sites (TNF-1371 and
TWIST1-524) are promising leads for potential diagnostic
purposes, they were detected from a relatively small data-
set of 46 samples. Accordingly, the reliability of the TNF
and TWIST CpG sites as biomarkers for lung cancer
requires further validation in larger datasets and through
targeted biological experiments.
Patterns vs. profile distances
Figure 5 displays the DNA methylation profiles of TNF-
1371 and TWIST1-524 from 12 lung cancer and 12 nor-
mal tissue samples in the testing dataset. The profiles of
normal tissue samples are generally uniform and consist-
ent, while the profiles of cancer samples are highly varia-
ble. This likely reflects the biological complexity of cancer.
To classify samples from different groups, a classification
method should have the ability to recognize all the pat-
Loading plot of 1596 CpG sites on the first two principal components for normal and lung cancer tissue dataset in PCA analysis Figure 3
Loading plot of 1596 CpG sites on the first two principal components for normal and lung cancer tissue dataset 
in PCA analysis. Most features cluster around the origin point, indicating that they contribute very little to the first two prin-
cipal components.BMC Bioinformatics 2008, 9:457 http://www.biomedcentral.com/1471-2105/9/457
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terns belonging to each group. Hierarchical clustering
(HC) is generally used for class prediction in gene expres-
sion analysis. However, HC is neither an appropriate nor
effective classification method. First, HC is considered an
unsupervised technique, since no sample class informa-
tion is utilized in the clustering. Thus, the output from HC
is simply a clustering tree, and no class information about
new samples is provided. Secondly, HC splits samples
into groups on the basis of similarity measured by dis-
tances of profiles. However, classification is a pattern-
identification problem, and the distances between pro-
files do not exactly reflect the real patterns leading to the
classification. As shown in Figure 5, lung cancer samples
have diverse patterns, and it is neither possible to cluster
them nor to distinguish them from normal tissue samples
purely based on distances among methylation profiles,
regardless of the distance measurement (correlation or
Euclidean distance) and linkage method (single, com-
plete, or average) used. FW_SVM, on the other hand,
employs SVM, a supervised machine learning technique,
as the classification method. Instead of using profile dis-
tance, SVM is able to learn and draw patterns for different
classes from labeled training samples. By capturing the
Pathway analysis of genes that contain the 100 most differentially methylated CpG sites between normal and lung cancer tissue  samples (p-value < 0.005). Genes that do not connect to other genes are not shown in this figure Figure 4
Pathway analysis of genes that contain the 100 most differentially methylated CpG sites between normal and 
lung cancer tissue samples (p-value < 0.005). Genes that do not connect to other genes are not shown in this 
figure.BMC Bioinformatics 2008, 9:457 http://www.biomedcentral.com/1471-2105/9/457
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essentials of the pattern recognition, SVM provides a gen-
erally accurate class prediction, as shown in this study.
Conclusion
This study shows that it is feasible to identify DNA meth-
ylation biomarkers from high-throughput DNA methyla-
tion profiles and that a small number of signature CpG
sites can suffice to classify two groups of samples. Signa-
ture CpG sites can easily be detected from datasets with
clear methylation patterns, such as male and female data-
sets, using traditional feature selection methods like indi-
vidual feature ranking. However, the traditional feature
selection methods were not efficient to identify signature
CpG sites from disease samples with complex DNA meth-
ylation patterns, such as the lung cancer tissue examined
in this study. We investigated two filter methods for
SVM_RFE in the study and built up FW_SVM, a predictor
with an efficient feature selection method. FW_SVM was
able to detect a small, optimal subset of CpG sites with
non-redundant and complementary discriminative infor-
mation and achieved high predictive accuracy to classify
disease samples with complex DNA methylation patterns.
Since each CpG site represents a feature, and the methyla-
tion level of each CpG site simply corresponds to the
value of the feature, the FW_SVM algorithm, in principle,
could be extended to analyze other post-genomic datasets,
such as high-throughput gene expression, microRNA
expression, single nucleotide polymorphisms, and pro-
teomic data, individually or even across platforms, to
identify combinatorial signature features. Therefore,
FW_SVM represents a highly flexible tool that can be
adopted in classification situations in which appropriate
high-throughput data are available to potentially aid in
diagnosis and gain fundamental insight into disease proc-
esses.
Availability and requirements
Project name: FW_SVM
Project home page: None. Matlab scripts for FW_SVM
were submitted to BMC Bioinformatics as additional file
1.
Operating system: platform independent
Programming language: Matlab
Other requirements: Work together with LS-SVMlab tool-
box that can be downloaded from: http://
www.esat.kuleuven.ac.be/sista/lssvmlab/
License: None
Any restrictions to use by non-academics: None
Authors' contributions
HM developed and implemented the algorithm under the
supervision of GL and ELM. The initial manuscript draft
was written by HM, and refined by GL and ELM.
Additional material
Acknowledgements
We thank Dr. Suykens for allowing us to use the LS_SVMlab toolbox in the 
implementation of FW_SVM. We are also grateful to George Patskan, Bar-
bara Zedler, Andrew Joyce, Madhukar Dasika, Tapas Sengupta, Jonathan 
Stephenson, Gaurav Rana, Priyadashi Basu, Edwin van den Oord, Eileen Iva-
sauskas and Janis Worth for reviewing this manuscript.
Additional file 1
Matlab scripts for FW_SVM.  FW_SVM is a biomarker discovery algo-
rithm and it can identify a small optimal subset of CpG sites from high-
throughput DNA methylation profiles to distinguish two sample groups. 
FW_SVM combined Filter method and Wrapper method as a novel two-
stage feature selection method and employed SVM as the classifier.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-457-S1.zip]
DNA methylation profiles of two signature CpG sites (TNF-1371 and TWIST1-524) from 12 lung cancer and 12 normal tissue  samples in the testing dataset Figure 5
DNA methylation profiles of two signature CpG sites (TNF-1371 and TWIST1-524) from 12 lung cancer and 
12 normal tissue samples in the testing dataset. The green color indicates low methylation level and red indicates high 
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